Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
… this program from Ionis Pharmaceuticals in October 2018. Scientific Updates During the second quarter of 2019, the … Company presented new data on the ProQR portfolio at three scientific conferences, including the annual meeting of … the Company presented at the 2019 annual Usher connections conference in July 2019. Business Updates In May 2019, …